Status of accelerator-based BNCT projects worldwide

Kiyanagi, Yoshiaki; Sakurai, Yoshinori; Kumada, Hiroaki; Tanaka, Hiroki

doi:10.1063/1.5127704

Cited by 56 publications

(45 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, only Japan uses these facilities for treatment purposes. However, in some other countries several new projects have been proposed and the new BNCT facilities are under construction, including those in Finland, China, Taiwan and Argentina [115,116]. Recently, Hirose et al [116] reported the initial results of the phase-II trial of AB-BNCT by using cyclotron-based neutron generator and 10 BPA in patients with recurrent and locally advanced head and neck cancer.…”

Section: Accelerator-based Bnct (Ab-bnct)mentioning

confidence: 99%

Boron Chemistry for Medical Applications

2020

View full text Add to dashboard Cite

Boron compounds now have many applications in a number of fields, including Medicinal Chemistry. Although the uses of boron compounds in pharmacological science have been recognized several decades ago, surprisingly few are found in pharmaceutical drugs. The boron-containing compounds epitomize a new class for medicinal chemists to use in their drug designs. Carboranes are a class of organometallic compounds containing carbon (C), boron (B), and hydrogen (H) and are the most widely studied boron compounds in medicinal chemistry. Additionally, other boron-based compounds are of great interest, such as dodecaborate anions, metallacarboranes and metallaboranes. The boron neutron capture therapy (BNCT) has been utilized for cancer treatment from last decade, where chemotherapy and radiation have their own shortcomings. However, the improvement in the already existing (BPA and/or BSH) localized delivery agents or new tumor-targeted compounds are required before realizing the full clinical potential of BNCT. The work outlined in this short review addresses the advancements in boron containing compounds. Here, we have focused on the possible clinical implications of the new and improved boron-based biologically active compounds for BNCT that are reported to have in vivo and/or in vitro efficacy.

show abstract

Section: Accelerator-based Bnct (Ab-bnct)mentioning

confidence: 99%

Boron Chemistry for Medical Applications

2020

View full text Add to dashboard Cite

show abstract

“…In addition to the intrinsic risk of the nuclear reactor, it is impossible to establish a reactor-based BNCT or perform subsequent treatment in a hospital. However, the miniaturized accelerator system is currently the most viable solution [ 29 , 30 ]. Many countries have established different types of accelerators for clinical BNCT treatment, such as cyclotron-, linac-, and electrostatic-based accelerators, most of which are located in Japan.…”

Section: Discussionmentioning

confidence: 99%

Salvage Boron Neutron Capture Therapy for Malignant Brain Tumor Patients in Compliance with Emergency and Compassionate Use: Evaluation of 34 Cases in Taiwan

Chen

Lee

Lin

et al. 2021

Biology

Self Cite

View full text Add to dashboard Cite

Although boron neutron capture therapy (BNCT) is a promising treatment option for malignant brain tumors, the optimal BNCT parameters for patients with immediately life-threatening, end-stage brain tumors remain unclear. We performed BNCT on 34 patients with life-threatening, end-stage brain tumors and analyzed the relationship between survival outcomes and BNCT parameters. Before BNCT, MRI and 18F-BPA-PET analyses were conducted to identify the tumor location/distribution and the tumor-to-normal tissue uptake ratio (T/N ratio) of 18F-BPA. No severe adverse events were observed (grade ≥ 3). The objective response rate and disease control rate were 50.0% and 85.3%, respectively. The mean overall survival (OS), cancer-specific survival (CSS), and relapse-free survival (RFS) times were 7.25, 7.80, and 4.18 months, respectively. Remarkably, the mean OS, CSS, and RFS of patients who achieved a complete response were 17.66, 22.5, and 7.50 months, respectively. Kaplan–Meier analysis identified the optimal BNCT parameters and tumor characteristics of these patients, including a T/N ratio ≥ 4, tumor volume < 20 mL, mean tumor dose ≥ 25 Gy-E, MIB-1 ≤ 40, and a lower recursive partitioning analysis (RPA) class. In conclusion, for malignant brain tumor patients who have exhausted all available treatment options and who are in an immediately life-threatening condition, BNCT may be considered as a therapeutic approach to prolong survival.

show abstract

“…Applications of ion beams in multidisciplinary physics are a long-standing tradition of LNL. These activities are carried out mainly at the AN2000 10 and CN 11 Van de Graaff accelerators and partly at the Tandem 12 . The CN (1-6 MV) and AN2000 (0.2-2.2 MV) provide a total of 12 beamlines and deliver around 2,700 h/year of beamtime ( 1 H, 2 H, 3 He, 4 He, 14 N, and 15 N).…”

Section: Infn and Cnaomentioning

confidence: 99%

“…Fast neutrons have been used in the past for cancer therapy but then dismissed because of inacceptable toxicities [7]. Epithermal and thermal neutrons can, however, effectively kill tumors loaded with 10 B, the so-called boron-neutron capture therapy (BNCT) [8,9]. BNCT has been hampered by the necessity of using nuclear reactors for treatment but is now revived by the perspective of using dedicated proton accelerators [10].…”

Section: Introductionmentioning

confidence: 99%

“…Epithermal and thermal neutrons can, however, effectively kill tumors loaded with 10 B, the so-called boron-neutron capture therapy (BNCT) [ 8 , 9 ]. BNCT has been hampered by the necessity of using nuclear reactors for treatment but is now revived by the perspective of using dedicated proton accelerators [ 10 ]. Cyclotrons and synchrotrons for charged-particle therapy are blooming worldwide [ 11 – 13 ], and many of these centers have intense preclinical research programs [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Biomedical Research Programs at Present and Future High-Energy Particle Accelerators

et al. 2020

View full text Add to dashboard Cite

Biomedical applications at high-energy particle accelerators have always been an important section of the applied nuclear physics research. Several new facilities are now under constructions or undergoing major upgrades. While the main goal of these facilities is often basic research in nuclear physics, they acknowledge the importance of including biomedical research programs and of interacting with other medical accelerator facilities providing patient treatments. To harmonize the programs, avoid duplications, and foster collaboration and synergism, the International Biophysics Collaboration is providing a platform to several accelerator centers with interest in biomedical research. In this paper, we summarize the programs of various facilities in the running, upgrade, or construction phase.

show abstract

Status of accelerator-based BNCT projects worldwide

Cited by 56 publications

References 13 publications

Boron Chemistry for Medical Applications

Boron Chemistry for Medical Applications

Salvage Boron Neutron Capture Therapy for Malignant Brain Tumor Patients in Compliance with Emergency and Compassionate Use: Evaluation of 34 Cases in Taiwan

Biomedical Research Programs at Present and Future High-Energy Particle Accelerators

Contact Info

Product

Resources

About